** Shares of Tylenol maker Kenvue KVUE.N rise 4.2% to $24.08 premarket
** KVUE says it earned a profit of 24 cents per share vs analysts' estimates of 23 cents per share - data compiled by LSEG
** Reports Q1 revenue of $3.74 billion vs estimates of $3.67 billion
** KVUE expects 2025 profit to remain flat year-over-year, anticipating higher costs from President Trump's tariffs on U.S. imports
** Co had previously forecast 2025 profit to be flat to 2% growth
** Separately, company appoints Amit Banati as chief financial officer, effective May 12
** Up to last close, stock has risen 8.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.